文献速递心力衰竭与心肌病

心力衰竭患者达到最大耐受β受体阻滞剂剂量:还有改进空间吗?

Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本文综述β受体阻滞剂改善慢性射血分数降低心衰临床结局的机制,描述关键临床试验与常规实践中达到的剂量差异,讨论不耐受原因及以剂量和心率为治疗靶点的证据,并为临床医生启动和上调β受体阻滞剂提供建议。

要点

  • β受体阻滞剂持续降低慢性射血分数降低心衰患者的死亡率和心衰住院。
  • 关键临床试验与常规临床实践中达到的β受体阻滞剂剂量存在差异。
  • 以β受体阻滞剂剂量和心率为治疗靶点的证据及不耐受原因被讨论。

核心结论

  • β受体阻滞剂持续降低慢性射血分数降低心衰患者的死亡率和心衰住院,但最大耐受剂量的定义及如何达到尚不完全清楚。

研究设计与样本

  • 综述:总结已发表报告中β受体阻滞剂改善临床结局的机制,并描述关键临床试验与常规临床实践中达到的剂量差异。

主要发现

  • β受体阻滞剂改善慢性射血分数降低心衰临床结局的机制包括神经激素阻断和心率降低。
  • 关键临床试验与常规临床实践中达到的β受体阻滞剂剂量存在差异。
  • 文章讨论了不耐受的原因以及使用β受体阻滞剂剂量和心率作为治疗靶点的证据。

临床怎么用

  • 文章为临床医生主动启动和上调β受体阻滞剂提供建议,可能有助于达到最大耐受剂量。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure (HF) is associated with significant morbidity and mortality. Although initially thought to be harmful in HF, beta-adrenergic blockers (β-blockers) have consistently been shown to reduce mortality and HF hospitalization in chronic HF with reduced ejection fraction. Proposed mechanisms include neurohormonal blockade and heart rate reduction. A new therapeutic agent now exists to target further heart rate lowering in patients who have been stable on a "maximally tolerated β-blocker dose," but this definition and how to achieve it are incompletely understood. In this review, the authors summarize published reports on the mechanisms by which β-blockers improve clinical outcomes. The authors describe differences in doses achieved in landmark clinical trials and those observed in routine clinical practice. They further discuss reasons for intolerance and the evidence behind using β-blocker dose and heart rate as therapeutic targets. Finally, the authors offer recommendations for clinicians actively initiating and up-titrating β-blockers that may aid in achieving maximally tolerated doses.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bhatt AS, DeVore AD, DeWald TA, et al. Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? J Am Coll Cardiol. 2017. PMID: 28521892. doi:10.1016/j.jacc.2017.03.563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。